Krystal Biotech is trading at $324.06 (5% down) in pre-market action, following several days of volatility after a strong multi-quarter run.
- The move appears tied to a broader risk-off tone in equities rather than fresh company-specific news or earnings reports.
- Major U.S. indices and futures are under pressure as investors react to geopolitical tensions and risks associated with higher interest rates.
- High-growth names are seeing a significant repricing as market sentiment shifts toward a more cautious stance.